TREX1 Inactivation Unleashes Cancer Cell STING–Interferon Signaling and Promotes Antitumor Immunity
Authors:
- Tetsuo TaniTTTetsuo Tani
- Haritha MathsyarajaHMHaritha Mathsyaraja
- Marco CampisiMarco Campisi
- Ze-Hua LiZLZe-Hua Li
- Koji HarataniKHKoji Haratani
- Caroline G. FaheyCFCaroline G. Fahey
- Keiichi OtaKOKeiichi Ota
- Navin R. MahadevanNMNavin R. Mahadevan
- Yingxiao ShiYSYingxiao Shi
- Shin SaitoSSShin Saito
- Kei MizunoKMKei Mizuno
- Tran C. ThaiTTTran C. Thai
Top Cited Papers
- 10 January 2024
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 14 (5) , 752-765
Abstract
A substantial fraction of cancers evade immune detection by silencing Stimulator of Interferon Genes (STING)-Interferon (IFN) signaling. Therapeutic reactivation of this program via STING agonists, epigenetic, or DNA-damaging therapies can restore antitumor immunity in multiple preclinical models. Here we show that adaptive induction of three prime exonuclease 1 (TREX1) restrains STING-dependent nucleic acid sensing in cancer cells via its catalytic function in degrading cytosolic DNA. Cancer cell TREX1 expression is coordinately induced with STING by autocrine IFN and downstream STAT1, preventing signal amplification. TREX1 inactivation in cancer cells thus unleashes STING–IFN signaling, recruiting T and natural killer (NK) cells, sensitizing to NK cell–derived IFNγ, and cooperating with programmed cell death protein 1 blockade in multiple mouse tumor models to enhance immunogenicity. Targeting TREX1 may represent a complementary strategy to induce cytosolic DNA and amplify cancer cell STING–IFN signaling as a means to sensitize tumors to immune checkpoint blockade (ICB) and/or cell therapies. Significance: STING–IFN signaling in cancer cells promotes tumor cell immunogenicity. Inactivation of the DNA exonuclease TREX1, which is adaptively upregulated to limit pathway activation in cancer cells, recruits immune effector cells and primes NK cell–mediated killing. Targeting TREX1 has substantial therapeutic potential to amplify cancer cell immunogenicity and overcome ICB resistance. This article is featured in Selected Articles from This Issue, p. 695Keywords
All Related Versions
Funding Information
- N/A (n/a)
This publication has 32 references indexed in Scilit:
- p53 engages the cGAS/STING cytosolic DNA sensing pathway for tumor suppressionMolecular Cell, 2023
- MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancerCancer Cell, 2022
- Hallmarks of response, resistance, and toxicity to immune checkpoint blockadeCell, 2021
- Intrinsic strategies for the evasion of cGAS-STING signaling-mediated immune surveillance in human cancer: How therapy can overcome themPharmacological Research, 2021
- ER-directed TREX1 limits cGAS activation at micronucleiMolecular Cell, 2021
- TREX1 – Apex predator of cytosolic DNA metabolismDNA Repair, 2020
- Tumor-Derived cGAMP Triggers a STING-Mediated Interferon Response in Non-tumor Cells to Activate the NK Cell ResponseImmunity, 2018
- Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRASCancer Cell, 2018
- TREX1 acts in degrading damaged DNA from drug-treated tumor cellsDNA Repair, 2009
- Trex1 Prevents Cell-Intrinsic Initiation of AutoimmunityCell, 2008